These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25029692)

  • 1. Stimulant treatment for ADHD.
    Verma R; Apala ; Kumari S; Dhiman V
    Br J Psychiatry; 2014 Jun; 204(6):490. PubMed ID: 25029692
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2014 Jun; 204(6):490-1. PubMed ID: 25029693
    [No Abstract]   [Full Text] [Related]  

  • 3. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2013 Aug; 203(2):112-9. PubMed ID: 23846996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medications used in the treatment of disruptive behavior in children with FASD--a guide.
    Ozsarfati J; Koren G
    J Popul Ther Clin Pharmacol; 2015; 22(1):e59-67. PubMed ID: 25715382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone in comorbid ADHD and ODD/CD.
    Kewley GD
    J Am Acad Child Adolesc Psychiatry; 1999 Nov; 38(11):1327-8. PubMed ID: 10560215
    [No Abstract]   [Full Text] [Related]  

  • 9. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A symposium on Attention Deficit Hyperactivity Disorder (ADHD). Developments in treatment.
    Levy F
    Aust N Z J Psychiatry; 2002 Aug; 36(4):477-9. PubMed ID: 12169142
    [No Abstract]   [Full Text] [Related]  

  • 11. Pemoline in ADHD.
    Winsberg B; Barbato M
    J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321
    [No Abstract]   [Full Text] [Related]  

  • 12. Self-handicapping prior to academic-oriented tasks in children with attention deficit/hyperactivity disorder (ADHD): medication effects and comparisons with controls.
    Waschbusch DA; Craig R; Pelham WE; King S
    J Abnorm Child Psychol; 2007 Apr; 35(2):275-86. PubMed ID: 17195950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of OROS methylphenidate on encopresis in children with attention-deficit/hyperactivity disorder.
    Yılmaz S; Bilgiç A; Hergüner S
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):158-60. PubMed ID: 24168715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
    Rothermel B; Poustka L; Banaschewski T; Becker K
    Z Kinder Jugendpsychiatr Psychother; 2010 Mar; 38(2):123-9; quiz 130. PubMed ID: 20200829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADHD: monitoring for and managing stimulant adverse effects.
    Mercer M; Farver D
    S D Med; 2013 Dec; 66(12):511, 513. PubMed ID: 24527549
    [No Abstract]   [Full Text] [Related]  

  • 19. Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome.
    Freudenreich O; Cather C; Holt D
    Am J Psychiatry; 2006 Nov; 163(11):2019. PubMed ID: 17074965
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends in antipsychotic use for youth with attention-deficit/hyperactivity disorder and disruptive behavior disorders.
    dosReis S; Saini J; Hong K; Reeves G; Spence OM
    Pharmacoepidemiol Drug Saf; 2022 Jul; 31(7):810-814. PubMed ID: 35484637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.